439 related articles for article (PubMed ID: 11786505)
1. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins.
Wiesbauer F; Kaun C; Zorn G; Maurer G; Huber K; Wojta J
Br J Pharmacol; 2002 Jan; 135(1):284-92. PubMed ID: 11786505
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering.
Haslinger B; Goedde MF; Toet KH; Kooistra T
Kidney Int; 2002 Nov; 62(5):1611-9. PubMed ID: 12371961
[TBL] [Abstract][Full Text] [Related]
3. Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity.
Aarons CB; Cohen PA; Gower A; Reed KL; Leeman SE; Stucchi AF; Becker JM
Ann Surg; 2007 Feb; 245(2):176-84. PubMed ID: 17245169
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death.
Knapp AC; Huang J; Starling G; Kiener PA
Atherosclerosis; 2000 Sep; 152(1):217-27. PubMed ID: 10996358
[TBL] [Abstract][Full Text] [Related]
5. Effects of simvastatin on cigarette smoke extract induced tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in human umbilical vein endothelial cells.
Hu XY; Ma YH; Wang C; Yang YH
Chin Med J (Engl); 2009 Oct; 122(19):2380-5. PubMed ID: 20079143
[TBL] [Abstract][Full Text] [Related]
6. Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells.
Mussoni L; Banfi C; Sironi L; Arpaia M; Tremoli E
Thromb Haemost; 2000 Jul; 84(1):59-64. PubMed ID: 10928471
[TBL] [Abstract][Full Text] [Related]
7. Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells.
Haslinger B; Kleemann R; Toet KH; Kooistra T
Kidney Int; 2003 Jun; 63(6):2065-74. PubMed ID: 12753293
[TBL] [Abstract][Full Text] [Related]
8. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
Dichtl W; Dulak J; Frick M; Alber HF; Schwarzacher SP; Ares MP; Nilsson J; Pachinger O; Weidinger F
Arterioscler Thromb Vasc Biol; 2003 Jan; 23(1):58-63. PubMed ID: 12524225
[TBL] [Abstract][Full Text] [Related]
9. Statins decrease TNF-alpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro.
Ben-Tal Cohen E; Hohensinner PJ; Kaun C; Maurer G; Huber K; Wojta J
Biochem Pharmacol; 2007 Jan; 73(1):77-83. PubMed ID: 17070781
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Turner NA; Midgley L; O'Regan DJ; Porter KE
J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315
[TBL] [Abstract][Full Text] [Related]
11. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells.
Lopez S; Peiretti F; Bonardo B; Juhan-Vague I; Nalbone G
Atherosclerosis; 2000 Oct; 152(2):359-66. PubMed ID: 10998463
[TBL] [Abstract][Full Text] [Related]
12. Effect of statins on the proteasomal activity in mammalian endothelial and vascular smooth muscle cells.
Ludwig A; Friedel B; Metzkow S; Meiners S; Stangl V; Baumann G; Stangl K
Biochem Pharmacol; 2005 Aug; 70(4):520-6. PubMed ID: 15996638
[TBL] [Abstract][Full Text] [Related]
13. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages.
Luan Z; Chase AJ; Newby AC
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):769-75. PubMed ID: 12663370
[TBL] [Abstract][Full Text] [Related]
14. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
Jantzen F; Könemann S; Wolff B; Barth S; Staudt A; Kroemer HK; Dahm JB; Felix SB; Landsberger M
J Physiol Pharmacol; 2007 Sep; 58(3):503-14. PubMed ID: 17928646
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ.
Wagner AH; Schwabe O; Hecker M
Br J Pharmacol; 2002 May; 136(1):143-9. PubMed ID: 11976279
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation.
White CM
J Clin Pharmacol; 1999 Feb; 39(2):111-8. PubMed ID: 11563401
[TBL] [Abstract][Full Text] [Related]
17. Statins inhibited erythropoietin-induced proliferation of rat vascular smooth muscle cells.
Kaneda T; Tsuruoka S; Fujimura A
Eur J Pharmacol; 2010 Dec; 649(1-3):38-43. PubMed ID: 20851116
[TBL] [Abstract][Full Text] [Related]
18. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells.
Bourcier T; Libby P
Arterioscler Thromb Vasc Biol; 2000 Feb; 20(2):556-62. PubMed ID: 10669656
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic effects of statins in atherosclerosis and diabetes.
Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.
Takeshita Y; Takamura T; Hamaguchi E; Shimizu A; Ota T; Sakurai M; Kaneko S
Metabolism; 2006 Nov; 55(11):1464-72. PubMed ID: 17046548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
